Bernstein analyst Florent Cespedes maintained a Buy rating on GlaxoSmithKline (GSK – Research Report) today and set a price target of £22.90.

Goldman Sachs analyst Rajan Sharma maintained a Hold rating on GlaxoSmithKline (GSK – Research Report) today and set a price target of £16.80.

Feb 15 (Reuters) - The U.S. Food and Drug Administration approved British drugmaker GSK's (GSK.L), opens new tab combination vaccine to protect against meningococcal infection for use in people ...

Feb 14 (Reuters) - Billionaire Ken Griffin's hedge fund Citadel has taken a short position in British drugmaker GSK (GSK.L), opens new tab, the Financial Times reported on Friday. Citadel has ...

Now, GSK is ready to play catch-up after nabbing its own FDA approval. The FDA approved the British drugmaker's Penmenvy vaccine to protect people ages 10 to 25 against meningococcal serogroups A ...

When investing, your capital is at risk. The value of your investments can go down as well as up and you may get back less than you put in. The content of this article is provided for information ...

GSK has claimed its second breakthrough designation from the FDA for antibody-drug conjugate GSK5764227, which it licensed from China's Hansoh Pharma in a $1.7 billion deal. The status has been ...

GSK's business development team have been working overtime of late, with three R&D deals announced in the last few days across Alzheimer's disease and cancer. The Alzheimer's agreement – with ...

Teva Pharmaceutical Industries Ltd. ADR-2.29% $19.01B ...

Perform in-depth fundamental analysis with decades of income statements, balance sheets, and cash flows — all exportable.

The Controller Bar and XBOX Game Pass widget make it easier to play. Windows 11 is the most secure version of Windows yet. It's important for security to be invisible so you can focus on using your PC ...